Adan Rios

2.0k total citations
67 papers, 1.2k citations indexed

About

Adan Rios is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Adan Rios has authored 67 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 17 papers in Pathology and Forensic Medicine and 15 papers in Hematology. Recurrent topics in Adan Rios's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Acute Myeloid Leukemia Research (10 papers). Adan Rios is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Acute Myeloid Leukemia Research (10 papers). Adan Rios collaborates with scholars based in United States, Belgium and Egypt. Adan Rios's co-authors include Jorge R. Quesada, Jordan U. Gutterman, Michael G. Rosenblum, David A. Swanson, J. U. Gutterman, Patrick W. Trown, Moshe Talpaz, Razelle Kurzrock, Stephen A. Sherwin and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Adan Rios

54 papers receiving 1.1k citations

Peers

Countries citing papers authored by Adan Rios

Since Specialization

Citations

This map shows the geographic impact of Adan Rios's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adan Rios with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adan Rios more than expected).

Fields of papers citing papers by Adan Rios

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adan Rios. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adan Rios. The network helps show where Adan Rios may publish in the future.

Co-authorship network of co-authors of Adan Rios

This figure shows the co-authorship network connecting the top 25 collaborators of Adan Rios. A scholar is included among the top collaborators of Adan Rios based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adan Rios. Adan Rios is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ABCL-1145: Unusual Extranodal Sites of Diffuse Large B-Cell Lymphoma 2025 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), (unknown), (unknown), Adan Rios	0
2	AML-713 Hematological Malignancies and Pregnancy: A Single-Institution Experience 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), (unknown), (unknown), Sean Blackwell, Baha M. Sibai, Adan Rios	0
3	Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring 2024 ·SHILAP Revista de lepidopterología ·Binsah George, Kok Hoe Chan, Adan Rios	0
4	AML-046 Real World Data on Clinical Outcomes of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated With Hypomethylating Agents (HMA) Plus Shorter Duration of Venetoclax (VEN) at a General Hospital 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Hina Khan, (unknown), (unknown), Adan Rios	0
5	Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets 2023 ·Expert Opinion on Investigational Drugs ·Joshua Morse, (unknown), (unknown), Adan Rios, Cheng Cheng Zhang, Naval Daver, Courtney D. DiNardo, Ningyan Zhang, Zhiqiang An	5
6	Reduced-Intensity Anthracycline-Free Chemoimmunotherapy in Elderly Patients With Newly Diagnosed or Relapsed Diffuse Large B-Cell Lymphoma 2023 ·Journal of Hematology ·(unknown), Adan Rios	1
7	Primary Diffuse Large B-Cell Lymphoma of the Bone 2023 ·Journal of Hematology ·(unknown), Adan Rios	2
8	AML-102 Infectious Complications in Acute Myeloid Leukemia (AML) Patients Undergoing Induction Chemotherapy With Fludarabine/Cladribine, Cytarabine, and Idarubicin (FIA/CLIA): A Single-Center Retrospective Study 2023 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Akanksha Sharma, (unknown), Adan Rios	0
9	Durable remission with Bruton’s tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma 2022 ·BMJ Case Reports ·(unknown), Arthi Sridhar, Nghia D. Nguyen, Adan Rios	1
10	Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies 2022 ·Biomedicines ·(unknown), (unknown), Anneliese Gonzalez, Adan Rios	9
11	Fundamental challenges to the development of a preventive HIV vaccine 2018 ·Current Opinion in Virology ·Adan Rios	12
12	Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide 2016 ·Oncoscience ·Adan Rios, Sigmund Hsu, Angel I. Blanco, (unknown), Arthur L. Day, Mary F. McGuire, Robert Brown	31
13	HER3/ErbB3, an emerging cancer therapeutic target 2015 ·Acta Biochimica et Biophysica Sinica ·Ningyan Zhang, (unknown), Adan Rios, Zhiqiang An	59
14	Expression of Constitutively Activated NF-κB/mTORC Pathway Proteins and Response to CHOP With Bortezomib in a Patient With Angioimmunoblastic Peripheral T-Cell Lymphoma 2014 ·Clinical Lymphoma Myeloma & Leukemia ·Andres Quesada, Adan Rios, Robert Brown, Nghia D. Nguyen	1
15	Kaposi Sarcoma in the Setting of Cushing Disease 2011 ·Endocrine Practice ·(unknown), Adan Rios, Mary D. Ruppe, (unknown)	1
16	Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature 2003 ·Leukemia Research ·Apostolia M. Tsimberidou, Jorge Medina, Jörge E. Cortes, Adan Rios, (unknown), Stefan Faderl, Hagop Kantarjian, Guillermo Garcia‐Manero	9
17	Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related burkitt lymphoma/leukemia 2002 ·Cancer ·Jörge E. Cortes, Deborah A. Thomas, Adan Rios, Charles Koller, Susan O’Brien, Sima Jeha, Stefan Faderl, Hagop M. Kantarjian	115
18	RELATIONSHIP OF EXPOSURE TO HUMAN T LYMPHOTROPIC VIRUS AND T HELPER CELLS IN HOMOSEXUAL MEN 1986 ·PubMed ·James M. Reuben, (unknown), (unknown), (unknown), Adan Rios, Evan M. Hersh, Peter W. A. Mansell	3
19	Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant Gamma-Interferon in Cancer Patients 1985 ·Oncology ·Razelle Kurzrock, Michael G. Rosenblum, Stephen A. Sherwin, Adan Rios, Moshe Talpaz, Jorge R. Quesada, Jordan U. Gutterman	50
20	Leukocyte subset analysis and related immunological findings in acquired immunodeficiency disease syndrome (AIDS) and malignancies. 1983 ·PubMed ·E. M. Hersh, (unknown), (unknown), Adan Rios, Guy R. Newell, A L Goldstein, Kara L. Lynch	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact